
May 1, 2019 Research and Development AbbVie, HCV, hepatitis C, mavyret, pharma

May 1, 2019 Research and Development, Sales and Marketing Contepo, Nabriva, pharma, urinary tract infections

May 1, 2019 Research and Development UTHealth, clinical trials, diabetes, smoking smoking cessation

May 1, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, appointment, pharma

May 1, 2019 Research and Development AD, Alzheimer's, dementia, late, neuroscience

April 30, 2019 Manufacturing and Production, Research and Development Cimzia, UCB Pharma, pharma, plaque psoriasis, psoriasis

April 29, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing

April 26, 2019 Medical Communications, Research and Development, Sales and Marketing Gilead, nash, pharma, selonsertib

April 26, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Aduro Biotech, Cancer, GSK, ICR, J&J, JJ, Novartis, Sandoz, pharma

April 26, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

April 25, 2019 Medical Communications, Research and Development, Sales and Marketing Cancer, ICR, R&D, access, cancer drugs, incentives, innovation, oncology, pricing
April 25, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cambridge, NDA, drug development

April 25, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Sandoz, appointment, pharma

April 25, 2019 Research and Development angina, cilostazol, dementia, heart drugs, isosorbide mononitrate, stroke

April 24, 2019 Research and Development PhRMA, Trump, USA, congress, lobbying, lobbyists, pharma